More on NMRA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+18.2% Growth)
- Ratings (6.4 Score)

Upcoming Events

- Earnings (8/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Neumora Therapeutics (NQ:NMRA)
Delayed: 1.66 +0.17 (11.41%)
Prev. Close $1.49  
Open$1.51 
52 Wk High$ 
52 Wk Low$ 
Day High$1.71 
Day Low$1.50 
P/E N/A  
EPS$ 
Volume811,072 


Jul 27, 2026 07:08 AM Form 8-K Neumora Therapeutics, For: Jul 27
Jul 27, 2026 07:01 AM Neumora clears toxicology hurdle for NMRA-215, plans 2026 IND filing
Jul 27, 2026 07:00 AM Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Jul 13, 2026 07:26 AM Neumora Therapeutics (NMRA) PT Lowered to $5 at RBC Capital
Jun 22, 2026 06:45 AM Neumora Therapeutics (NMRA) PT Lowered to $4 at Mizuho
Jun 16, 2026 07:12 AM Neumora Therapeutics (NMRA) PT Lowered to $5 at Needham
Jun 16, 2026 06:46 AM Neumora Therapeutics (NMRA) PT Lowered to $7 at H.C. Wainwright
Jun 15, 2026 08:15 AM Form 8-K Neumora Therapeutics, For: Jun 10
Jun 15, 2026 08:01 AM Neumora Therapeutics (NMRA) Halted, News Pending
Jun 15, 2026 08:00 AM Neumora discontinues navacaprant after phase 3 trials fail primary endpoints
View All Articles

Entities mentioned with NMRA

View All Entities